Terms: = Kidney tumors AND HNRNPA2B1, ENSG00000122566, SNRPB1, RNPA2, HNRPB1, HNRPA2, HNRNPB1, HNRNPA2, 3181 AND Treatment
4 results:
1. LINC00645 inhibits renal cell carcinoma progression by interacting with hnrnpa2b1 to regulate the ROCK1 mRNA stability.
Li H; Han X; Song L; Li X; Zhang L; Jin Z; Zhang Y; Wang T; Huang Z; Jia Z; Yang J
Gene; 2024 May; 905():148232. PubMed ID: 38309317
[TBL] [Abstract] [Full Text] [Related]
2. Identification of a New Prognostic Risk Signature of Clear Cell Renal Cell Carcinoma Based on N
Zhang Y; Yao Y; Qi X; Li J; Liu M; Che X; Xu Y; Wu G
J Immunol Res; 2021; 2021():6617841. PubMed ID: 33628845
[TBL] [Abstract] [Full Text] [Related]
3. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
Nanus DM; Garino A; Milowsky MI; Larkin M; Dutcher JP
Cancer; 2004 Oct; 101(7):1545-51. PubMed ID: 15378501
[TBL] [Abstract] [Full Text] [Related]
4. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function.
Carles J; Nogué M; Domènech M; Pérez C; Saigí E; Villadiego K; Guasch I; Ibeas R
Oncology; 2000 Jun; 59(1):24-7. PubMed ID: 10895062
[TBL] [Abstract] [Full Text] [Related]
